Prostate cancer implant could replace systemic hormone shots
NCT ID NCT04943536
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tests whether a bicalutamide implant placed directly into the prostate can replace standard hormone shots for men with localized prostate cancer receiving radiation. About 20 participants with intermediate- or high-risk cancer will receive the implant plus radiation. The goal is to see if this targeted approach is safe and feasible, potentially reducing side effects from whole-body hormone therapy.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALIZED PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Cancer Institute
Bethesda, Maryland, 20894, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can surgery boost control of spread prostate cancer?
- Can sound waves offer a lasting fix for prostate problems?
- Can a better scan sharpen radiation for prostate cancer?
- A sharper eye on prostate cancer: could new imaging spare healthy tissue?
- Hormone therapy showdown: can an oral pill beat the shot for prostate cancer patients?
- Can tracking tumor movement during radiation make treatment more precise?